Tamoxifen and Antidepressants Combo Increase Risk of Breast Cancer Return

Results of a new study show that some popular antidepressants, like Zoloft, Paxil and Prozac, can negate the effectiveness of the breast cancer drug tamoxifen, substantially increasing the risk that the tumors may return.

A tamoxifen study by Medco Health Solutions, which was presented Saturday at a meeting of the American Society of Clinical Oncology, found that a certain class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs), negate much of the effectiveness of tamoxifen, doubling the chance that the breast cancer will return when compared to women taking tamoxifen alone.

Researchers looked at 1,300 women taking tamoxifen to treat breast cancer. Those patients who were taking tamoxifen and antidepressant SSRI drugs together had a 14 percent chance of tumors recurring, while those taking tamoxifen alone had only a 7.5 percent chance. The study found that Paxil, Zoloft and Prozac had the highest increased breast cancer risk, at 16 percent.

Did You Know?

Millions of Philips CPAP Machines Recalled

Philips DreamStation, CPAP and BiPAP machines sold in recent years may pose a risk of cancer, lung damage and other injuries.

Learn More

While doctors and researchers have long suspected a connection between SSRIs and decreased effectiveness of tamoxifen, this study is the first large-scale study to confirm the risk.

About half a million women take tamoxifen in the United States, and the study raises serious concerns that a large percentage may be negating its effectiveness unknowingly. Nearly 30% of breast cancer survivors taking tamoxifen use some form of antidepressant to treat hot flashes, which are a side effect of tamoxifen.

SSRIs are part of a larger group of drugs called CYP2D6 inhibitors. Weaker CYP2D6 inhibitors, like Luvox and Lexapro, did not raise the recurrence risk for breast cancer patients. However, the study found that 60 percent of the women taking a CYP2D6 were using an SSRI.

Medco researchers say that physicians must be warned about the negative side effects of antidepressant SSRIs combined with tamoxifen. While the link has been studied for some time, many physicians are still unaware of the risk.

Image Credit: |

4 Comments

  • tommieJuly 20, 2012 at 4:54 am

    I took tamoxifin for five years as well as prozac. Last Nov. I had a bilateral mactectomy. I have been prescribed arimadex since aggressive cancer cells were found in the removed tissue.

  • silk214November 16, 2011 at 4:29 pm

    OMG - My sister has been taking tamoxifen and cymbalata for years and her pharmacy just told her to stop because the tamoxifen is much less effective. This info was know as early as 2009 and no one is telling breast cancer patients... This is really awful!!!!!

  • MichelleJuly 30, 2010 at 11:22 pm

    If anyone got SKIN CANCER FROM ZOLOFT please contact me! I just met another lady, a nurse, who has had it for 10 years like myself. Lets pull together to fight this and have them help us to stop the invasion of the skin cancers attacking out bodies from the medication that was suppose to be safe.

  • JULIEJuly 20, 2010 at 4:18 pm

    I was on prozac for about 5 years while on tamoxifen for about 1-1/2 years for breast cancer, it came back a second time so now I do not take either med

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Fairness of Philips CPAP Recall Settlement Being Evaluated By MDL Judge
Fairness of Philips CPAP Recall Settlement Being Evaluated By MDL Judge (Posted today)

A federal judge has held a fairness hearing for a proposed Philips CPAP class action lawsuit settlement, which seeks to resolve claims that consumers suffered economic damages due to the massive recall over toxic sound abatement foam.